{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:54:47Z","timestamp":1773273287620,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1007\/s11912-006-0034-4","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T17:19:59Z","timestamp":1180113599000},"page":"282-288","source":"Crossref","is-referenced-by-count":28,"title":["Methadone for treatment of cancer pain"],"prefix":"10.1007","volume":"8","author":[{"given":"John","family":"Bryson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anoo","family":"Tamber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dori","family":"Seccareccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"34_CR1","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1001\/jama.290.18.2476","volume":"290","author":"E Bruera","year":"2003","unstructured":"Bruera E, Kim HN: Cancer pain. JAMA 2003, 290:2476\u20132479.","journal-title":"JAMA"},{"key":"34_CR2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/0140-6736(92)90546-F","volume":"339","author":"GW Hanks","year":"1992","unstructured":"Hanks GW, Justins DM: Cancer pain: management. Lancet 1992, 339:1031\u20131036.","journal-title":"Lancet"},{"key":"34_CR3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/082585970101700208","volume":"17","author":"S Watanabe","year":"2001","unstructured":"Watanabe S: Methadone: the renaissance. J Palliat Care 2001, 17:117\u2013120.","journal-title":"J Palliat Care"},{"key":"34_CR4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s005200000180","volume":"9","author":"MP Davis","year":"2001","unstructured":"Davis MP, Walsh D: Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 2001, 9:73\u201383. This is a useful review, particularly regarding pharmacologic aspects of methadone and relevant drug interactions.","journal-title":"Support Care Cancer"},{"key":"34_CR5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0889-8588(02)00017-5","volume":"16","author":"C Ripamonti","year":"2002","unstructured":"Ripamonti C, Bianchi M: The use of methadone for cancer pain. Hematol Oncol Clin North Am 2002, 16:543\u2013555.","journal-title":"Hematol Oncol Clin North Am"},{"key":"34_CR6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0014-2999(99)00270-8","volume":"373","author":"JG Liu","year":"1999","unstructured":"Liu JG, Liao XP, Gong ZH, Qin BY: The difference between methadone and morphine in regulation of delta-opioid receptors underlies the antagonistic effect of methadone on morphine-mediated cellular actions. Eur J Pharmacol 1999, 373:233\u2013239.","journal-title":"Eur J Pharmacol"},{"key":"34_CR7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3940(97)13391-2","volume":"223","author":"AL Gorman","year":"1997","unstructured":"Gorman AL, Elliott KJ, Inturrisi CE: The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett 1997, 223:5\u20138.","journal-title":"Neurosci Lett"},{"key":"34_CR8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0304-3959(95)00073-2","volume":"62","author":"J Mao","year":"1995","unstructured":"Mao J, Price DD, Mayer DJ: Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 1995, 62:259\u2013274.","journal-title":"Pain"},{"key":"34_CR9","first-page":"1263","volume":"274","author":"EE Codd","year":"1995","unstructured":"Codd EE, Shank RP, Schupsky JJ, Raffa RB: Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther 1995, 274:1263\u20131270.","journal-title":"J Pharmacol Exp Ther"},{"key":"34_CR10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0304-3959(88)90290-4","volume":"33","author":"JL Plummer","year":"1988","unstructured":"Plummer JL, Gourlay GK, Cherry DA, Cousins MJ: Estimation of methadone clearance: application in the management of cancer pain. Pain 1988, 33:313\u2013322.","journal-title":"Pain"},{"key":"34_CR11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1056-8719(00)00043-5","volume":"42","author":"MJ Garrido","year":"1999","unstructured":"Garrido MJ, Troconiz IF: Methadone: a review of its pharmacokinetic\/ pharmacodynamic properties. J Pharmacol Toxicol Methods 1999, 42:61\u201366.","journal-title":"J Pharmacol Toxicol Methods"},{"key":"34_CR12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1526-4637.2002.02047.x","volume":"3","author":"SM Fishman","year":"2002","unstructured":"Fishman SM, Wilsey B, Mahajan G, Molina P: Methadone reincarnated: novel clinical applications with related concerns. Pain Med 2002, 3:339\u2013348.","journal-title":"Pain Med"},{"key":"34_CR13","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1200\/JCO.1998.16.10.3216","volume":"16","author":"C Ripamonti","year":"1998","unstructured":"Ripamonti C, Groff L, Brunelli C, et al.: Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 1998, 16:3216\u20133221.","journal-title":"J Clin Oncol"},{"key":"34_CR14","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.0.CO;2-3","volume":"82","author":"PG Lawlor","year":"1998","unstructured":"Lawlor PG, Turner KS, Hanson J, Bruera ED: Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer 1998, 82:1167\u20131173.","journal-title":"Cancer"},{"key":"34_CR15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1008263910494","volume":"9","author":"C Ripamonti","year":"1998","unstructured":"Ripamonti C, De Conno F, Groff L, et al.: Equianalgesic dose\/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. Ann Oncol 1998, 9:79\u201383.","journal-title":"Ann Oncol"},{"key":"34_CR16","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T","volume":"78","author":"E Bruera","year":"1996","unstructured":"Bruera E, Pereira J, Watanabe S, et al.: Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996, 78:852\u2013857.","journal-title":"Cancer"},{"key":"34_CR17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s005200050029","volume":"8","author":"MP Davis","year":"2000","unstructured":"Davis MP: Methadone as a rescue for failed high-dose opiate therapy for catastrophic pain. Support Care Cancer 2000, 8:138\u2013140.","journal-title":"Support Care Cancer"},{"key":"34_CR18","first-page":"25","volume":"19","author":"C Zimmermann","year":"2005","unstructured":"Zimmermann C, Seccareccia D, Booth CM, Cottrell W: Rotation to methadone after opioid dose escalation: How should individualization of dosing occur? J Pain Palliat Care Pharmacother 2005, 19:25\u201331.","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"34_CR19","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1046\/j.1440-1681.2000.03290.x","volume":"27","author":"MT Smith","year":"2000","unstructured":"Smith MT: Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol.Physiol 2000, 27:524\u2013528.","journal-title":"Clin Exp Pharmacol.Physiol"},{"key":"34_CR20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1191\/096813098673619329","volume":"5","author":"JS Morley","year":"1998","unstructured":"Morley JS, Makin MK: The use of methadone in cancer pain poorly responsive to other opioids. Pain Rev 1998, 5:51\u201358.","journal-title":"Pain Rev"},{"key":"34_CR21","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1200\/JCO.1999.17.10.3307","volume":"17","author":"S Mercadante","year":"1999","unstructured":"Mercadante S, Casuccio A, Calderone L: Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol 1999, 17:3307\u20133312.","journal-title":"J Clin Oncol"},{"key":"34_CR22","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1200\/JCO.2005.13.128","volume":"23","author":"S Mercadante","year":"2005","unstructured":"Mercadante S, Ferrera P, Villari P, Casuccio A: Rapid switching between transdermal fentanyl and methadone in cancer patients. J Clin Oncol 2005, 23:5229\u20135234. This interesting study proposes a rapid conversion method for rotating from transdermal fentanyl to oral methadone and vice versa. It is important in being the first to evaluate rotation from fentanyl, and the authors also report on conversion in the opposite direction, from methadone to fentanyl.","journal-title":"J Clin Oncol"},{"key":"34_CR23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0885-3924(99)00083-4","volume":"18","author":"NA Hagen","year":"1999","unstructured":"Hagen NA, Wasylenko E: Methadone: outpatient titration and monitoring strategies in cancer patients. J Pain Symptom Manage 1999, 18:369\u2013375.","journal-title":"J Pain Symptom Manage"},{"key":"34_CR24","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/oxfordjournals.annonc.a010679","volume":"7","author":"S Mercadante","year":"1996","unstructured":"Mercadante S, Sapio M, Serretta R, Caligara M: Patientcontrolled analgesia with oral methadone in cancer pain: preliminary report. Ann Oncol 1996, 7:613\u2013617.","journal-title":"Ann Oncol"},{"key":"34_CR25","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1200\/JCO.1996.14.10.2836","volume":"14","author":"F Conno De","year":"1996","unstructured":"De ConnoF, Groff L, Brunelli C, et al.: Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol 1996, 14:2836\u20132842.","journal-title":"J Clin Oncol"},{"key":"34_CR26","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s005200100266","volume":"9","author":"ED Dickerson","year":"2001","unstructured":"Dickerson ED: Methadone: the question or the answer for US opioid therapy and pharmaco-economics? Support Care Cancer 2001, 9:646\u2013648.","journal-title":"Support Care Cancer"},{"key":"34_CR27","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1200\/JCO.1998.16.11.3656","volume":"16","author":"S Mercadante","year":"1998","unstructured":"Mercadante S, Casuccio A, Agnello A, et al.: Morphine versus methadone in the pain treatment of advancedcancer patients followed up at home. J Clin Oncol 1998, 16:3656\u20133661.","journal-title":"J Clin Oncol"},{"key":"34_CR28","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0885-3924(99)00048-2","volume":"18","author":"S Mercadante","year":"1999","unstructured":"Mercadante S, Casuccio A, Agnello A, Barresi L: Methadone response in advanced cancer patients with pain followed at home. J Pain Symptom Manag 1999, 18:188\u2013192.","journal-title":"J Pain Symptom Manag"},{"key":"34_CR29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2004.03.172","volume":"22","author":"E Bruera","year":"2004","unstructured":"Bruera E, Palmer JL, Bosnjak S, et al.: Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 2004, 22:185\u2013192. This is a rigorously conducted randomized double-blind trial of methadone versus morphine as a first-line opioid for cancer pain.","journal-title":"J Clin Oncol"},{"key":"34_CR30","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S0885-3924(99)00049-4","volume":"18","author":"B Gagnon","year":"1999","unstructured":"Gagnon B, Bruera E: Differences in the ratios of morphine to methadone in patients with neuropathic pain versus nonneuropathic pain. J Pain Symptom Manag 1999, 18:120\u2013125.","journal-title":"J Pain Symptom Manag"},{"key":"34_CR31","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1017\/S0317167100004236","volume":"32","author":"DE Moulin","year":"2005","unstructured":"Moulin DE, Palma D, Watling C, Schulz V: Methadone in the management of intractable neuropathic noncancer pain. Can J Neurol Sci 2005, 32:340\u2013343.","journal-title":"Can J Neurol Sci"},{"key":"34_CR32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1155\/2003\/236718","volume":"8","author":"B Gagnon","year":"2003","unstructured":"Gagnon B, Almahrezi A, Schreier G: Methadone in the treatment of neuropathic pain. Pain Res Manag 2003, 8:149\u2013154.","journal-title":"Pain Res Manag"},{"key":"34_CR33","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1191\/0269216303pm815oa","volume":"17","author":"JS Morley","year":"2003","unstructured":"Morley JS, Bridson J, Nash TP, et al.: Low-dose methadone has an analgesic effect in neuropathic pain: a doubleblind randomized controlled crossover trial. Palliat Med 2003, 17:576\u2013587.","journal-title":"Palliat Med"},{"key":"34_CR34","doi-asserted-by":"crossref","unstructured":"Nicholson AB: Methadone for cancer pain. Cochrane Database Syst Rev 2004, CD003971. This comprehensive review of randomized controlled trials evaluates the effectiveness and safety of methadone compared with other opioids.","DOI":"10.1002\/14651858.CD003971.pub2"},{"key":"34_CR35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1089\/10966210252785097","volume":"5","author":"E Bruera","year":"2002","unstructured":"Bruera E, Sweeney C: Methadone use in cancer patients with pain: a review. J Palliat Med 2002, 5:127\u2013138.","journal-title":"J Palliat Med"},{"key":"34_CR36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1155\/2005\/286713","volume":"10","author":"ME Lynch","year":"2005","unstructured":"Lynch ME: A review of the use of methadone for the treatment of chronic noncancer pain. Pain Res Manag 2005, 10:133\u2013144.","journal-title":"Pain Res Manag"},{"key":"34_CR37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0304-3959(91)90179-2","volume":"45","author":"E Bruera","year":"1991","unstructured":"Bruera E, Fainsinger R, Moore M, et al.: Local toxicity with subcutaneous methadone. Experience of two centers. Pain 1991, 45:141\u2013143.","journal-title":"Pain"},{"key":"34_CR38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0885-3924(99)00020-2","volume":"18","author":"P Mathew","year":"1999","unstructured":"Mathew P, Storey P: Subcutaneous methadone in terminally ill patients: manageable local toxicity. J Pain Symptom Manag 1999, 18:49\u201352.","journal-title":"J Pain Symptom Manag"},{"key":"34_CR39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/J354v19n02_03","volume":"19","author":"C Centeno","year":"2005","unstructured":"Centeno C, Vara F: Intermittent subcutaneous methadone administration in the management of cancer pain. J Pain Palliat Care Pharmacother 2005, 19:7\u201312.","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"34_CR40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0304-3959(96)03313-1","volume":"70","author":"PL Manfredi","year":"1997","unstructured":"Manfredi PL, Borsook D, Chandler SW, Payne R: Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations. Pain 1997, 70:99\u2013101.","journal-title":"Pain"},{"key":"34_CR41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0304-3959(97)00118-8","volume":"73","author":"DR Fitzgibbon","year":"1997","unstructured":"Fitzgibbon DR, Ready LB: Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine. Pain 1997, 73:259\u2013261.","journal-title":"Pain"},{"key":"34_CR42","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.1987.47","volume":"41","author":"CE Inturrisi","year":"1987","unstructured":"Inturrisi CE, Colburn WA, Kaiko RF, et al.: Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 1987, 41:392\u2013401.","journal-title":"Clin Pharmacol Ther"},{"key":"34_CR43","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1365-2125.2004.02116.x","volume":"58","author":"O Dale","year":"2004","unstructured":"Dale O, Sheffels P, Kharasch ED: Bioavailabilities of rectal and oral methadone in healthy subjects. Br J Clin Pharmacol 2004, 58:156\u2013162.","journal-title":"Br J Clin Pharmacol"},{"key":"34_CR44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0304-3959(94)00257-F","volume":"62","author":"E Bruera","year":"1995","unstructured":"Bruera E, Watanabe S, Fainsinger RL, et al.: Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. Pain 1995, 62:141\u2013146.","journal-title":"Pain"},{"key":"34_CR45","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/oxfordjournals.annonc.a059327","volume":"6","author":"C Ripamonti","year":"1995","unstructured":"Ripamonti C, Zecca E, Brunelli C, et al.: Rectal methadone in cancer patients with pain. A preliminary clinical and pharmacokinetic study. Ann Oncol 1995, 6:841\u2013843.","journal-title":"Ann Oncol"},{"key":"34_CR46","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/clpt.1988.159","volume":"44","author":"DS Weinberg","year":"1988","unstructured":"Weinberg DS, Inturrisi CE, Reidenberg B, et al.: Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988, 44:335\u2013342.","journal-title":"Clin Pharmacol Ther"},{"key":"34_CR47","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1053\/bean.2002.0253","volume":"16","author":"D Kedlaya","year":"2002","unstructured":"Kedlaya D, Reynolds L, Waldman S: Epidural and intrathecal analgesia for cancer pain. Best Pract Res Clin Anaesthesiol 2002, 16:651\u2013665.","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"34_CR48","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0304-3959(90)91066-R","volume":"43","author":"L Jacobson","year":"1990","unstructured":"Jacobson L, Chabal C, Brody MC, et al.: Intrathecal methadone: a dose-response study and comparison with intrathecal morphine 0.5 mg. Pain 1990, 43:141\u2013148.","journal-title":"Pain"},{"key":"34_CR49","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00002508-199112000-00014","volume":"7","author":"Y Shir","year":"1991","unstructured":"Shir Y, Shapira SS, Shenkman Z, et al.: Continuous epidural methadone treatment for cancer pain. Clin J Pain 1991, 7:339\u2013341.","journal-title":"Clin J Pain"},{"key":"34_CR50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF03020415","volume":"49","author":"P Prieto-Alvarez","year":"2002","unstructured":"Prieto-Alvarez P, Tello-Galindo I, Cuenca-Pena J, et al.: Continuous epidural infusion of racemic methadone results in effective postoperative analgesia and low plasma concentrations. Can J Anaesth 2002, 49:25\u201331.","journal-title":"Can J Anaesth"},{"key":"34_CR51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/jpm.2000.3.49","volume":"3","author":"IL Mancini","year":"2000","unstructured":"Mancini IL, Hanson J, Neumann CM, Bruera ED: Opioid type and other clinical predictors of laxative dose in advanced cancer patients: a retrospective study. J Palliat Med 2000, 3:49\u201356.","journal-title":"J Palliat Med"},{"key":"34_CR52","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/082585970001600209","volume":"16","author":"D Oneschuk","year":"2000","unstructured":"Oneschuk D, Bruera E: Respiratory depression during methadone rotation in a patient with advanced cancer. J Palliat Care 2000, 16:50\u201354.","journal-title":"J Palliat Care"},{"key":"34_CR53","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/00007691-200208000-00001","volume":"24","author":"K Wolff","year":"2002","unstructured":"Wolff K: Characterization of methadone overdose: clinical considerations and the scientific evidence. Ther Drug Monit 2002, 24:457\u2013470.","journal-title":"Ther Drug Monit"},{"key":"34_CR54","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0304-3959(02)00461-X","volume":"103","author":"PW Walker","year":"2003","unstructured":"Walker PW, Klein D, Kasza L: High dose methadone and ventricular arrhythmias: a report of three cases. Pain 2003, 103:321\u2013324.","journal-title":"Pain"},{"key":"34_CR55","doi-asserted-by":"crossref","first-page":"501","DOI":"10.7326\/0003-4819-137-6-200209170-00010","volume":"137","author":"MJ Krantz","year":"2002","unstructured":"Krantz MJ, Lewkowiez L, Hays H, et al.: Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002, 137:501\u2013504.","journal-title":"Ann Intern Med"},{"key":"34_CR56","doi-asserted-by":"crossref","first-page":"154","DOI":"10.7326\/0003-4819-139-2-200307150-00021","volume":"139","author":"BA Martell","year":"2003","unstructured":"Martell BA, Arnsten JH, Ray B, Gourevitch MN: The impact of methadone induction on cardiac conduction in opiate users. Ann.Intern.Med. 2003, 139:154\u2013155.","journal-title":"Ann.Intern.Med"},{"key":"34_CR57","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0304-3959(03)00205-7","volume":"105","author":"CA Kornick","year":"2003","unstructured":"Kornick CA, Kilborn MJ, Santiago-Palma J, et al.: QTc interval prolongation associated with intravenous methadone. Pain 2003, 105:499\u2013506.","journal-title":"Pain"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-006-0034-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-006-0034-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-006-0034-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:31:29Z","timestamp":1559435489000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-006-0034-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["34"],"URL":"https:\/\/doi.org\/10.1007\/s11912-006-0034-4","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}